Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP507748.RABnu8D-YpwTHw4aODG30rgcJ1J1bwNXFKH_mZKanAh_c130_assertion description "[Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP507748.RABnu8D-YpwTHw4aODG30rgcJ1J1bwNXFKH_mZKanAh_c130_provenance.
• NP286674.RAr3HZ_AzR1tNQnmw8DTMMYt0pbd8Rd8AdGoigtHMr7J4130_assertion description "[Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP286674.RAr3HZ_AzR1tNQnmw8DTMMYt0pbd8Rd8AdGoigtHMr7J4130_provenance.
• NP417051.RA40y85Oj9A7CC8LBO76ypqZ19DJqdAimyZ7grCSRecdU130_assertion description "[Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP417051.RA40y85Oj9A7CC8LBO76ypqZ19DJqdAimyZ7grCSRecdU130_provenance.
• NP431818.RAJFdNyY7VlIBO8Emacebz10Vc8igGAxpb_AWxoIK4AwI130_assertion description "[Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP431818.RAJFdNyY7VlIBO8Emacebz10Vc8igGAxpb_AWxoIK4AwI130_provenance.
• assertion description "[Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP862636.RANXGdXFKt_RIzqTaTVbtyrf9PaT7ismHP-riQLG7DVjs130_assertion description "[Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP862636.RANXGdXFKt_RIzqTaTVbtyrf9PaT7ismHP-riQLG7DVjs130_provenance.
• NP883822.RAmsKJk2ca41PA9Zx7yykg6BiGUYOrV6Q-4l1vBSuW46I130_assertion description "[Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP883822.RAmsKJk2ca41PA9Zx7yykg6BiGUYOrV6Q-4l1vBSuW46I130_provenance.
• NP1083210.RAsdzsSgMwDrX0iD-gkOvDMWIfgpmt70mSmwZ5dUn-X7I130_assertion description "[Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1083210.RAsdzsSgMwDrX0iD-gkOvDMWIfgpmt70mSmwZ5dUn-X7I130_provenance.
• NP1083213.RApNkglV7nvTLihyvHgUbch7j_5wcXSEcIYtDg35e_Adc130_assertion description "[Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1083213.RApNkglV7nvTLihyvHgUbch7j_5wcXSEcIYtDg35e_Adc130_provenance.
• NP1083214.RArw-2Rv5KfJfIF-_qri_BQkEdv0pakuci-NOkg9ckXY0130_assertion description "[Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1083214.RArw-2Rv5KfJfIF-_qri_BQkEdv0pakuci-NOkg9ckXY0130_provenance.
• NP883818.RAN-aL0yvPiiCqs0VAKwy8A2vkNgrsOBTNxCUs-8nQkYc130_assertion description "[Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP883818.RAN-aL0yvPiiCqs0VAKwy8A2vkNgrsOBTNxCUs-8nQkYc130_provenance.
• NP883830.RAPCFiDPqI0dcdK0JgRTBgHfTi_b-AJ80p5oGMZ4MQKLI130_assertion description "[Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP883830.RAPCFiDPqI0dcdK0JgRTBgHfTi_b-AJ80p5oGMZ4MQKLI130_provenance.
• NP883817.RA8w2xjB6Nm9ciNW15mcLJETQ8a8tTzjR0qLxd7f3Sgq8130_assertion description "[Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP883817.RA8w2xjB6Nm9ciNW15mcLJETQ8a8tTzjR0qLxd7f3Sgq8130_provenance.
• NP1083211.RAxYNK0z1R-cjlOfFJDvzJnQLyDRbwu3HIDV6NYlS2pBM130_assertion description "[Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1083211.RAxYNK0z1R-cjlOfFJDvzJnQLyDRbwu3HIDV6NYlS2pBM130_provenance.